ALX ONCOLOGY HOLDINGS INC Impairment of Long-Lived Assets Held-for-use
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Impairment of Long-Lived Assets Held-for-use of $3.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-05-08
- ALX ONCOLOGY HOLDINGS INC impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- ALX ONCOLOGY HOLDINGS INC impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- ALX ONCOLOGY HOLDINGS INC impairment of long-lived assets held-for-use for the quarter ending 2025-06-30 was $3.20M.
- ALX ONCOLOGY HOLDINGS INC impairment of long-lived assets held-for-use for fiscal 2025 was $3.17M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $3.20M derived: sum of 3 quarters · filed 2026-05-08 | $3.17M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $3.20M derived: sum of 2 quarters · filed 2026-05-08 | $3.17M 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $3.20M 10-Q · filed 2026-05-08 | $3.17M 10-Q · filed 2025-08-12 | $3.17M 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |